Get the Stockscreener App
4.5938
9.12%
0.3838
Nanobiotix Adr stock is traded at $4.5938, with a volume of 8,587.
It is up +9.12% in the last 24 hours and down -11.49% over the past month.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.
See More
Previous Close:
$4.21
Open:
$4.1914
24h Volume:
8,587
Relative Volume:
1.05
Market Cap:
$199.10M
Revenue:
$27,600
Net Income/Loss:
$-62.02M
P/E Ratio:
-2.5921
EPS:
-1.7722
Net Cash Flow:
$-39.23M
1W Performance:
-1.84%
1M Performance:
-11.49%
6M Performance:
-24.69%
1Y Performance:
-22.73%
1-Day Range:
$4.1914
$4.20
1-Week Range:
$4.16
$4.70
52-Week Range:
$4.14
$8.962
Nanobiotix Adr Stock (NBTX) Company Profile
Nanobiotix Adr Stock (NBTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-06-21 | Initiated | Evercore ISI | Outperform |
Nanobiotix Adr Stock (NBTX) Latest News
Squamous Cell Carcinoma Clinical Trial Pipeline Insights: 75+ Key Companies Investigating Their Lead Candidates to Improve the Treatment Space | DelveInsight - GlobeNewswire Inc.
Nanobiotix (NASDAQ:NBTX) Trading Down 14% - Defense World
Nanobiotix (NASDAQ:NBTX) Stock Price Down 14% - MarketBeat
Nanobiotix S.A. (NASDAQ:NBTX) Forecasted to Earn FY2025 Earnings of $0.88 Per Share - MarketBeat
Earnings call: Nanobiotix reports Q1 2024 results, advances with NBTXR3 - Investing.com India
Earnings call: Nanobiotix reports Q1 2024 results, advances with NBTXR3 By Investing.com - Investing.com
NANOBIOTIX Co-Founder and CEO Laurent Levy Named to 2022 PharmaVoice 100 List of Most Inspiring People in ... - The Globe and Mail
Nanobiotix Announces Latest Share and Voting Rights UpdateTipRanks.com - TipRanks
Nanobiotix Prepares to Unveil Q1 2024 ResultsTipRanks.com - TipRanks
Nanobiotix's NBTXR3 Enters Phase 2 Lung Cancer StudyTipRanks.com - TipRanks
Nanobiotix's Revenue at Risk: The High Stakes of Sole Dependence on Janssen PartnershipTipRanks.com - TipRanks
Nanobiotix Sa ADR Updates Share Capital InfoTipRanks.com - TipRanks
Nanobiotix Advances NBTXR3 for Lung Cancer TreatmentTipRanks.com - TipRanks
NANOBIOTIX Annual Shareholders’ General Meeting to Be Held on June 23, 2022 - The Globe and Mail
NANOBIOTIX Announces 18.1 Month Median Overall Survival for 41 Evaluable Elderly and Frail Patients With HNSCC ... - The Globe and Mail
NANOBIOTIX Reports New Data for Potential First-in-Class Radioenhancer NBTXR3 in Combination With Anti-PD-1 Showing Local or Distant Tumor Regression in 76.9% of Evaluable Patients Regardless of Prior Anti-PD-1 Exposure - Business Wire
NANOBIOTIX Announces the Appointment of Bart Van Rhijn as Chief Financial Officer and Member of the Executive ... - The Globe and Mail
NANOBIOTIX Partners With LianBio to Develop and Commercialize Potential First-in-Class Radioenhancer NBTXR3 Across Tumor Types and Therapeutic Combinations in China and Other Asian Markets - Business Wire
IPO Launch: Nanobiotix S.A. Pursues $96 Million IPOIPOs On TheStreetU.S. IPO Research & Opinion - TheStreet
NBTX News Today | Why did Nanobiotix stock go down today? - MarketBeat
Nanobiotix (NBTX) Stock Price, News & Analysis - MarketBeat
Nanobiotix - Massachusetts Biotechnology Council
Nanobiotix Adr Stock (NBTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.75%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):